The IHC results demonstrated significant increases of protein expressions of FGF19, FGFR4 and EpCAM in specimens with fatty liver, NASH, cirrhosis, and HCC compared to healthy liver tissue. Here, FGFR4 is linked to metabolic dysfunction-associated steatohepatitis.